The Clinical Application and Popularization of Portable Home Noninvasive Ventilator
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hu Mingdong, MD
- Phone Number: +86-13500362524
- Email: huhanshandd@163.com
Study Locations
-
-
-
Chongqing, China
- Recruiting
- Emergency Department, Xinqiao Hospital, Third Military Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 40 years old < age < 80 years old
- COPD diagnosis was made according to GOLD guidelines
- The subjects with chronic type II respiratory failure
- The subjects with structural lung disease
- The subjects signed informed consent.
Exclusion Criteria:
- The subjects suffering from COPD acute exacerbation
- The subjects currently participating in other related products
- The subjects with organ dysfunction because of liver,kidney, hematopoietic system and serious metabolic disease endocrine system
- The subjects with poor compliance
- The subjects refused to sign the informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
The Portable Home Noninvasive Ventilator treatment group
The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
|
|
Routine home oxygen therapy group
The patient maintained a stable COPD regimen and conventional home oxygen therapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The frequency of the chronic obstructive pulmonary disease(COPD) acute exacerbation.
Time Frame: one year
|
Record the frequency of COPD acute exacerbation within one year
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The first onset time of the chronic obstructive pulmonary disease(COPD) acute exacerbation
Time Frame: one year
|
Record the first onset time of COPD acute exacerbation
|
one year
|
|
The number of hospitalizations due to the chronic obstructive pulmonary disease(COPD) acute exacerbation
Time Frame: one year
|
Record the number of hospitalizations due to the COPD acute exacerbation
|
one year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six Minute Walk Distance
Time Frame: month0,month4,month8,month12
|
month0,month4,month8,month12
|
|
|
pulmonary arterial pressure
Time Frame: month0,month4,month8,month12
|
month0,month4,month8,month12
|
|
|
arterial blood gas
Time Frame: month0,month4,month8,month12
|
month0,month4,month8,month12
|
|
|
routine analysis of blood
Time Frame: month0,month4,month8,month12
|
month0,month4,month8,month12
|
|
|
The change of cytokines expression
Time Frame: month0,month4,month8,month12
|
The cytokines including IL8、IL13、TNF-a、INF-r、IFN-γ、LTB4.
|
month0,month4,month8,month12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- cstc2016shmszx130034
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
NCT03745547CompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease
-
NCT05431218CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe
-
NCT05539547Not yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
NCT06629675RecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease
-
NCT04828837TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation
-
NCT03573817CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT01260389CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT04285047UnknownChronic Obstructive Pulmonary Disease (13645005)
-
NCT03644836CompletedBroncho Chronic Obstructive Pulmonary Disease
-
NCT02238483CompletedChronic Obstructive Pulmonary Disease COPD